Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Equities researchers at Capital One Financial increased their Q3 2024 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research note issued to investors on Wednesday, October 16th. Capital One Financial analyst N. Quibria now forecasts that the biopharmaceutical company will earn ($0.22) per share for the quarter, up from their previous forecast of ($0.25). The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Capital One Financial also issued estimates for Fennec Pharmaceuticals' Q4 2024 earnings at ($0.18) EPS and FY2024 earnings at ($0.03) EPS.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) EPS for the quarter, missing analysts' consensus estimates of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The firm had revenue of C$9.94 million during the quarter, compared to the consensus estimate of C$18.67 million.
Fennec Pharmaceuticals Trading Down 0.8 %
FRX traded down C$0.05 during trading on Monday, reaching C$6.40. 526 shares of the stock traded hands, compared to its average volume of 1,863. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The stock's 50-day moving average is C$7.03 and its 200 day moving average is C$9.14. Fennec Pharmaceuticals has a 12 month low of C$5.76 and a 12 month high of C$15.43. The stock has a market capitalization of C$175.10 million, a PE ratio of 64.00 and a beta of 0.25.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
